Telehealth vs. In-Person GLP-1 Clinics: Which Is Right for You?

Medically reviewed by a licensed healthcare professional. Last updated March 2026.

Key Takeaways

• Both telehealth and in-person GLP-1 treatment can produce clinically meaningful weight loss when supervised by qualified providers.
• Telehealth offers lower costs ($150-$350/month typical) and convenience, but cannot perform physical exams or in-office lab work.
• In-person clinics provide comprehensive medical evaluation, lab monitoring, and hands-on injection training.
• The DEA and most states now permit GLP-1 prescribing via telehealth without an in-person visit, though regulations vary by state ^[1].
• Your medical complexity, insurance coverage, and personal preferences should guide the decision.

The Growth of Telehealth GLP-1 Prescribing

Telehealth GLP-1 prescribing expanded dramatically after the COVID-19 public health emergency relaxed prescribing regulations. The Ryan Haight Act exemptions, extended through DEA rulemaking, now allow controlled substance prescribing via telehealth in most circumstances, and GLP-1 medications (which are not controlled substances) face even fewer restrictions ^[1].

As of 2025, dozens of telehealth platforms offer GLP-1 prescribing. Quality varies significantly. Some operate with board-certified obesity medicine physicians and comprehensive medical protocols; others use minimal screening and aggressive marketing. The platform matters as much as the delivery model.

How Each Model Works

Telehealth GLP-1 Clinics

A typical telehealth GLP-1 visit involves:

1. Online intake form — Medical history, current medications, BMI documentation, and contraindication screening
2. Video consultation — 15-30 minute appointment with a licensed prescriber (MD, DO, NP, or PA)
3. Prescription sent to pharmacy — Branded medications ship from a retail or specialty pharmacy; compounded medications typically ship directly from the provider's partner pharmacy
4. Follow-up visits — Monthly or bimonthly video check-ins during dose titration, transitioning to quarterly after reaching maintenance dose
5. Messaging support — Most platforms offer asynchronous messaging with clinical staff for questions between visits

In-Person GLP-1 Clinics

A typical in-person treatment program includes:

1. Initial consultation — Comprehensive medical evaluation including physical exam, vital signs, and BMI measurement
2. Lab work — Baseline bloodwork (comprehensive metabolic panel, A1c, lipid panel, thyroid function) ordered and reviewed
3. Injection training — Hands-on instruction for self-injection technique
4. Prescription — Written after the medical evaluation is complete
5. Follow-up visits — In-office appointments for weigh-ins, lab monitoring, dose adjustments, and side effect management
6. Ancillary services — Some clinics offer nutritional counseling, behavioral support, body composition analysis, and exercise programming

Clinical Outcomes: What the Evidence Shows

Limited head-to-head research compares telehealth versus in-person GLP-1 outcomes specifically. However, existing evidence from weight management studies suggests that telehealth-delivered obesity treatment produces comparable weight loss to in-person programs when both include regular provider contact and behavioral support ^[2].

A 2023 systematic review published in Obesity Reviews found that telehealth weight management interventions produced clinically significant weight loss (≥5% of body weight) at rates similar to face-to-face programs, with higher patient retention in the telehealth groups ^[2].

The key variable is not the delivery method but the quality of medical supervision — proper screening, appropriate dose titration, ongoing monitoring, and side effect management.

Cost Comparison

Cost structures differ substantially between telehealth and in-person models:

Telehealth Typical Costs

In-Person Typical Costs

Insurance coverage changes this calculation significantly. In-person visits are more commonly covered by medical insurance, and many in-person clinics handle prior authorization for branded medications. Most telehealth GLP-1 platforms operate on a cash-pay model and do not bill insurance, though this is changing.

Advantages and Limitations

Telehealth Advantages

• Convenience: No travel, no waiting rooms, appointments from home
• Lower cost: Reduced overhead translates to lower fees, especially when using compounded medications
• Access: Available to patients in rural areas or regions with few obesity medicine specialists
• Scheduling flexibility: Evening and weekend appointments are common
• Privacy: Some patients prefer the discretion of a virtual visit

Telehealth Limitations

• No physical examination: Providers cannot palpate the thyroid, check injection sites, or perform a hands-on assessment
• Lab work is the patient's responsibility: You will need to arrange your own blood draws at a local lab
• Injection training is virtual: Video instruction works for most patients but some prefer in-person demonstration
• Variable quality: The telehealth GLP-1 market includes both excellent providers and those with inadequate screening protocols
• Limited scope: Complex patients with multiple comorbidities may need in-person evaluation

In-Person Advantages

• Comprehensive evaluation: Physical exam, in-office lab work, and thorough medical assessment
• Hands-on injection training: Demonstrated directly with the patient
• Insurance billing: More likely to accept medical insurance and manage prior authorizations
• Ancillary services: Nutrition counseling, body composition analysis, and behavioral support often available on-site
• Continuity of care: Easier to coordinate with your primary care physician and specialists

In-Person Limitations

• Higher cost: Office overhead, staff, and facility costs result in higher fees
• Geographic barriers: Obesity medicine specialists are concentrated in urban areas
• Time commitment: Travel, waiting room time, and appointment scheduling constraints
• Limited hours: Most operate during standard business hours

Who Should Choose Telehealth?

Telehealth GLP-1 treatment is generally appropriate for patients who:

• Are otherwise healthy with no significant comorbidities beyond obesity
• Have a BMI of 30-40 with no history of pancreatitis, thyroid cancer, or MEN2 syndrome
• Are comfortable with self-injection after video training
• Can independently arrange baseline and periodic lab work
• Value convenience and cost savings
• Live in areas with limited access to in-person obesity medicine providers

Who Should Choose In-Person?

In-person treatment is generally preferable for patients who:

• Have complex medical histories (multiple medications, organ disease, surgical history)
• Have a BMI above 40 or severe obesity-related comorbidities
• Require frequent lab monitoring (kidney disease, liver disease, diabetes requiring insulin adjustment)
• Prefer hands-on injection training
• Want insurance to cover as much of the treatment as possible
• Are starting GLP-1 therapy for the first time and want a comprehensive initial evaluation

How to Evaluate Either Option

Regardless of whether you choose telehealth or in-person, apply the same quality standards:

1. Verify provider credentials — Licensed prescriber with relevant medical training
2. Confirm proper screening — Medical history review, contraindication check, and discussion of risks
3. Ask about monitoring — What follow-up schedule do they use? How do they handle side effects?
4. Understand pricing — What is the total monthly cost including visits, medication, and all fees?
5. Check medication sourcing — FDA-approved medications or 503B-registered compounding pharmacies

Browse telehealth GLP-1 providers or search our clinic directory for in-person options in your area, with verified credentials and patient reviews.

---

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.

Sources

1. DEA. "Expansion of Induction of Buprenorphine via Telemedicine Encounter and Second Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescribing Controlled Substances." https://www.deadiversion.usdoj.gov/pubs/docs/telemedicine_guidance.pdf
2. Seo Y, et al. "Telehealth Interventions for Obesity Management: A Systematic Review." Obesity Reviews. 2023;24(12):e13627. https://doi.org/10.1111/obr.13627
3. NIH National Institute of Diabetes and Digestive and Kidney Diseases. "Prescription Medications to Treat Overweight & Obesity." https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity
4. FDA. Wegovy Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
5. American Telemedicine Association. "State Telehealth Policy." https://www.americantelemed.org/policy/state-telehealth-policy/